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Calcitriol deficiency with retained synthetic reserve in chronic renal
failure. Serum calcitriol and the free calcitriol index together with
factors considered to regulate calcitriol production were measured in
eleven patients with moderate chronic renal failure (MCRF) and eleven
age- and sex-matched normal subjects. Although the serum dialysable
calcium levels were similar in the two groups, there was depression of
calcitriol levels and an elevation of PTH and nephrogenous cyclic AMP
(NcAMP) levels in the MCRF patients. Furthermore, plasma phosphate
levels were higher and the renal phosphate threshold was depressed in
this patient group. When all subjects were grouped together calcitriol
was positively correlated with GFR. When calcitriol levels were fac-
tored for GFR, to permit an assessment of calcitriol production per unit
functioning renal mass, there was no significant difference between
normal and MCRF subjects. To determine whether reserve for calcitriol
production existed, six of the MCRF patients and six of the age- and
sex-matched normal subjects received a low calcium diet for one week
supplemented by cellulose phosphate to bind calcium within the gut. In
both groups there was a significant rise in calcitriol, although the
absolute levels were much lower in the MCRF patients than the normal
subjects. These results suggest that calcitriol deficiency is a major
feature of MCRF despite marked hyperparathyroidism. The rise in
calcitriol levels in MCRF suggests persistent reserve secretory capacity
in this condition. Therefore, the low serum calcitriol concentration may
be due not only to structural renal damage, but also to suppression of
calcitriol formation perhaps due to altered renal phosphate handling.
The best recognized abnormality of calcium homeostasis
described in mild to moderate chronic renal failure (MCRF) is
hyperparathyroidism [1, 2]. The role of calcitriol in this situa-
tion is unclear with evidence for [3—6] and against [7, 8] low
circulating levels of calcitriol (I, 25-dihydroxyvitamin D). The
normal physiological inter-relationship between parathyroid
hormone (PTH) and calcitriol consists of a feedback loop in
which PTH stimulates calcitriol formation in the kidney [9]. The
rise in calcitriol stimulates increased gut calcium absorption
[101, and allows increased bone calcium resorption [11], thereby
raising extracellular calcium and suppressing PTH formation.
We present evidence for low basal levels of calcitriol in patients
with MCRF, and using a low calcium diet as a stress test, we
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demonstrate retained but reduced synthetic capacity for
calcitriol production.
Methods
Subjects
The study group consisted of 11 subjects with MCRF (nine
males and two females) mean age 40 (range 19 to 57) and 11 age-
and sex-matched normal volunteers with a mean age of 36
(range 26 to 54). The mean glomerular filtration rate (GFR) for
the MCRF patients was 44 mI/mm (range 20 to 78) and for the
normal subjects was 126 mI/mm (range 87 to 180). Patient
details are shown in Table 1. Approval for the study was ob-
tained from the Human Rights Committee of the University of
Western Australia. Informed consent was obtained from each
subject.
Basal study
All subjects had a 24-hour urine collection while on an
unrestricted diet. Following a twelve hour fast, a urine sample
was collected from 9:00 a.m. to 11:00 am, with a fasting
mid-point blood sample collected at 10:00 a.m.
Calcium deprivation study
The first six subjects with MCRF studied in the basal study
and six age- and sex-matched normal subjects participated in a
calcium deprivation study. Two baseline samples were col-
lected while the subjects were consuming their normal self-
selected diet. On day 0, after collection of the second baseline
sample, they commenced a low calcium intake for one week,
avoiding foods with a high calcium content, especially milk
products, eggs, seafood and certain vegetables. Detailed in-
structions on the diet were given at the beginning of the study
and reinforced at each visit. In addition oral cellulose phosphate
5 g four times a day was taken with food to bind calcium within
the gut lumen and thereby reduce the availability for absorption
of both dietary calcium and calcium in intestinal secretions [12].
To prevent magnesium deficiency, magnesium aspartate I g was
taken orally twice daily. Twenty-four-hour urine collections
were performed on days —5, —1, 1, 3 and 6. Fasting two-hour
urine samples with fasting mid-point plasma and serum samples
were collected on days —4, 0, 2, 4 and 7.
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Table 1. Clinical details of subjects with moderate chronic renal
failure
Glomerular
filtration
Patient Sex Age rate mi/mm Diagnosis
I Male 35 78 Polycystic kidneys
2 Male 39 25 Radiation nephritis
3 Male 45 44 Chronic glomerulonephritis
4 Male 25 50 Bladder neck obstruction
5 Female 51 33 Analgesic nephropathy
6 Female 38 31 Chronic glomerulonephritis
7 Male 54 78 Polyarteritis (stable)
8 Male 57 20 Chronic gomerulonephritis
9 Male 19 37 Reflux nephropathy
10 Male 57 59 Hypertension
II Female 20 32 Membranous glomerulonephritis
Analyses
All samples were analyzed for calcium, phosphate, urea and
creatinine concentrations using standard Technicon SMAC
methods. Cyclic 3'5'-adenosine monophosphate (cAMP) was
measured on the fasting two-hour urine samples by radioimmu-
noassay (RIA) using an antibody raised in rabbits; intra- and
interassay coefficients of variation were 12 and 14%, respec-
tively [13]. All plasma samples were analyzed for creatinine,
alkaline phosphatase and phosphate, using routine Technicon
SMAC methods; magnesium was measured using atomic ab-
sorption spectrophotometry. Serum samples were also ana-
lyzed for dialysable calcium, calcitriol and immunoreactive
PTH. Dialysable calcium, consisting of ionized and complexed
calcium, was measured using a modification of the Auto
Analyser II method for total calcium; the interassay coefficient
of variation was 0.7% and the correlation with ionized calcium
concentrations in normal subjects was 0.71 [14]. Calcitriol was
measured by bovine thymus cytoreceptor using a column
extraction technique [15]; intra- and interassay coefficients of
variation were 21% and 24%, respectively. PTH was measured
using a 'mid-region' specific antibody (IRE, Belgium) with
synthetic human PTH fragment 44-68 as standard and tracer;
intra- and interassay coefficients of variation were 8 and 16%,
respectively [16]. Serum cAMP values were measured after
ultrafiltration (CentriFree Micropartition System, Amicon.
Australia) using a RIA method used for urine; the interassay
coefficient of variation was 12%. Serum samples on day —4 and
7 were analyzed for 25-hydroxyvitamin D [25(OH)D] using rat
kidney cytosol [17]; intra- and interassay coefficients of varia-
tion were 8 and 20%, respectively. Serum vitamin D binding
protein (DBP) was measured by radial-immunodiffusion using
antiserum supplied by Dr. R. Bouillon [18]. All samples from
the same subject were analyzed in the same assay.
Calculations
Renal phosphate threshold (Tmp) was calculated from the
nomogram of Bijvoet and Morgan [191. Urinary cAMP
(UcAMP) was calculated per liter glomerular filtrate. Nephro-
genous cAMP (NcAMP) was calculated by subtracting cAMP
filtered at the glomerulus from total UcAMP [201. The free
calcitriol index was calculated as the molar ratio of calcitriol to
DBP using DBP levels measured on day 0 [181. Statistical
Table 2. Basal study results (mean sD)
Normal subjectsN=ll MRCF subjectsN=ll
-
Ageyr 36±8 40±14
Glomerular
filtration rate 125 30 20"
mi/mm
Serum dialysable
calcium ininol/liter 1.44 0.04 1.42 0.07
Plasma phosphate
mmollliter 1.02 0.09 1.25 0.22'
Serum PTH
pmoi Eq/liter 20 IS 187 147"
Nephrogenous
cAMP nmol/IGF 9.7 5.5 23.5 9.3"
Renal phosphate
threshold mmol/IGF 1.01 0.69 0.22e
Serum 25(OH)D
nmol/liter 84 32 81 35
Serum calcitriol
pmol/iiter 86 20 46 18"
Serum
calcitriol/GFR ratio 0.69 0.22 1.01 0.50
Serum DBP
mol/liter 6.4 2.0 6.8 1.0
Free calcitriol
ratio X 1O 1.26 0.30 0.69 0.29a
24-Hour urine
phosphate mmol/24 hr 38.1 12.4 36.4 10.9
24-Hour urine
calcium mmoi/24 hr 5.1 2.3 2.5 15b
24-Hour urine
creatinine mmol/24 hr 15.0 4.1 15.3 4.6
24-Hour urine
urea mmoi/24 hour 456 104 471 82
P < 0.02 of normal subjects
"P < 0.001 of normal subjects
evaluation was performed using the Statistical Package for
Social Science (SPSS 9). The unpaired Student's t-test was used
to compare MCRF patients with normal subjects. Statistical
analysis of changes during the calcium deprivation test for each
subject was limited to the use of the paired Student's f-test
comparing the mean of the two basal values and the values
occurring on the day of peak calcitriol concentration, which
was day four of the test for MCRF patients and day two of the
test for normal subjects. As the basal data was only used in one
comparison, a P value of less than 0.05 was considered signif-
icant. Linear regression analysis was performed using least
squares analysis.
Results
Basal study
Mean calcitriol levels were much lower in the MCRF subjects
than in the normal subjects (Table 2). This was not due to a
difference in DBP so that the calculated free calcitriol index was
also much lower in the MCRF subjects. The MCRF patients
also had clear biochemical evidence of hyperparathyroidism as
shown by elevated PTH and NcAMP levels. Despite the
marked changes in calcitriol and PTH levels the serum dialys-
able calcium was similar in the two groups. The plasma phos-
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phate levels were significantly higher in the MCRF subjects and
the Tm significantly lower.
When all subjects were considered together there was a
significant positive correlation between calcitriol and GFR (Fig.
1). In view of the marked reduction in functional renal mass in
the MCRF subjects, the ratio of calcitriol to GFR was calcu-
lated for each subject. This allowed an assessment of calcitriol
production factored for functional renal mass, thereby allowing
assessment of calcitriol production per unit of functioning
kidney. There was no significant difference in this ratio between
MCRF and normal subjects. There was a significant positive
correlation between the calcitriol/GFR ratio and both PTH and
NcAMP (Figs. 2, 3), and a significant negative correlation
between the calcitriol/GFR ratio and Tm (Fig. 4). However the
correlation between the calcitriol/GFR ratio and plasma phos-
phate was not significant. None of the above correlations were
significant when the MCRF patients and normal subjects were
considered as separate groups.
Twenty-four-hour urine excretion of creatinine, urea and
phosphate did not differ between MCRF patients and normal
subjects. However, calcium excretion was significantly lower in
MCRF patients.
Calcium deprivation test
During the low calcium diet the relationships between the
parameters discussed in the basal study were unaltered, so that
calcitriol, the free calcitriol index, Tmp and 24-hour urine
calcium were always significantly lower in the MCRF patients
than the normal subjects, while PTH, NcAMP and phosphate
were significantly higher in MCRF patients. Dialysable calcium
was similar in both groups. (Table 3, Figs. 5, 6)
In both normal and MCRF subjects the low calcium diet
resulted in a significant elevation in calcitriol and the free
calcitriol index (Fig. 5). The peak calcitriol level was lower and
occurred later in the MCRF patients than the normal subjects
(MCRF patients 76 31 pmol/liter on day 4; normal subjects
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Fig. 2. The correlation between the parathyroid hormone concentration
and serum caicitriol factored for giomerular filtration rate. Symbols as
in Fig. 1. Y = 0.002 x + 0.715; r = 0.6197; P = 0.003.
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Fig. 1. The correlation between the glomerular flit ration rate and serum
caicitriol concentration. Symbols are: (•) MCRF subjects; (x) normals.
Y = 0.315 x + 38.73; r = 0.551; P = 0.0097.
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Fig. 3. The correlation between nephrogenous cyclic AMP and serum
caicitriol factored for glomeruiarflitration rate. Symbols as in Fig. 1. Y
= 0.024 X + 0.538; r = 0.553; P = 0.009.
161 35 pmol/liter on day 2; Fig. 6). A significant fall in
dialysable calcium occurred in both the MCRF patients and
normal subjects. Plasma phosphate and Tmp fell significantly
only in normal subjects while PTH levels and NcAMP rose
significantly only in the MCRF patients. The 24-hour urine
calcium fell in both groups, but there was no overall change in
the 24-hour urine phosphate or urea in either group. There was
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Fig. 4. The correlation between the renal phosphate threshold and
serum calcitrwl factored jr glomerular filtration rate. Symbols as in
Fig. I. V = —0.915 X + l.719; r =
—0.496; P = 0.02.
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Fig. 6. Serum calcitriol concentration during seven days of calcium
deprivation. Symbols are in Fig. I. * P < 0.05 ** P < 0.01 P <0.001
normals compared to MCRF patients on that day by unpaired i-test.
Discussion
The most notable biochemical abnormality in the MCRF
subjects, apart from the evidence for hyperparathyroidism, was
the marked lowering of calcitriol levels determined either as
total calcitriol or as the free calcitriol ratio. Despite marked
changes in the two hormones, the plasma calcium levels were
unchanged, presumably because of the reciprocal nature of the
changes. The significant reduction in calcitriol levels in patients
with MCRF is supported by many [3—6] but not all [7, 81
published studies. It is however, clear that calcitriol levels in
some MCRF subjects are within the normal range. Despite
claims that calcitriol levels may be high in early chronic renal
failure [211 there is little data to support this [91. Although it is
generally agreed that in severe chronic renal failure calcitriol
levels are low, our study indicates that the degree of renal
failure cannot be the only factor determining calcitriol levels.
Although there was a positive correlation between calcitriol
levels and GFR when all subjects were considered, within the
group of MCRF patients alone there was no correlation be-
tween calcitriol levels and GFR, despite a range of GFR from 20
to 78 mI/mm. This suggests that the threshold GFR for the
lowering of calcitriol is above 78 mI/mm.
The ratio of calcitriol to GFR was calculated in an attempt to
evaluate the production of calcitriol per unit functioning renal
mass. This ratio assumes firstly that the major determinant of
circulating calcitriol levels is the rate of production, rather than
the metabolic clearance rate, and secondly that calculation of
the creatinine clearance is a good estimate of functioning renal
mass. The first of these assumptions has been examined in
normal subjects and little variation in metabolic clearance rate
found [22, 231. The second assumption is a reasonable approx-
imation [24].
In the basal study, the positive correlation between the
calcitriol/GFR ratio and both PTH and NcAMP suggests that,
when all subjects were considered together, a high PTH level
was a major determinant of high calcitriol production. Although
the plasma phosphate levels were higher in the MCRF subjects
160
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P< 0.01
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P< 0.02
Fig. 5. Basal and stimulated ca/curio! levels and basal and stimulated
calcitriol/GFR ratios in six normal subjects and subjects with ,noderate
chronic renal failure. Basal values are the mean of day —4 and day 0.
Stimulated values are on day 2 in normal subjects and day 4 in MCRF
subjects.
no significant change in plasma magnesium or 25(OH)D (Table
4). During the test the magnitude of the rise in the calcitriol/
GFR ratio was not significantly different between MCRF and
normal subjects (Fig. 5).
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Table 3. Results (mean SD) of the calcium deprivation test in normal subjects and moderate chronic renal failure subjects
Normal subjects MCRF subjects
Calcium Calcium
Basal deprivation Basal deprivation
Serum calcitriol
pmoi/liter 98 20 161 35" 49 21 77 31"
Calcitriol/GFR ratio 0.81 0.30 1.33 0.49 1.20 0.47 1.85 0.71
Vitamin D binding protein
amol/hter 7.48 1.03 — 6.92 0.94 —
Free calcitriol ratio
(x105) 1.61 0.40 2.36 0.60" 0.75 0.40 1.17 0.63
Serum dialysable calcium
mmol/liter 1.44 0.05 1.40 0.05" 1.43 0.05 1.36 o.o7
Parathyroid hormone
pmol eq/liter 24 15 26 12 214 178 259 176"
Nephrogenous cyclic AMP
nmol/IGF 7.3 8.1 9.5 3.2 21.9 12.0 32.6 20.8"
Renal phosphate threshold
m,noj//GF 1.15 0.09 0.09 0.iF' 0.60 0.15 0.56 0.07
Plasma phosphate
mmol/liter 1.10 0.05 0.97 007b 1.14 0.17 1.19 0.20
24-Hour urine phosphate
mmol/day 33.2 10.2 40.6 14.4 37.3 11.1 39.0 7.2
24-Hour urine calcium
mmol/day 4.5 2.1 1.9 0.9" 2.00 1.4 1.4 1.1"
24-Hour urine urea
mmol/day 417 127 437 179 463 72 410 80
24-Hour urine creatinine
mmol/day 14.2 5.2 16.0 5.7 16.0 4.9 14.9 4.00
The results shown during calcium deprivation are the results obtained at the time of the mean maximal calcitriol response, which was day 2 of the
test for normal subjects and day 4 of the test for MCRF subjects.
a P < 0.05 cf basal
b P < 0.02 cf basal
as a group than the normal subjects, the lack of correlation
between the calcitriol/GFR ratio and plasma phosphate sug-
gests that hyperphosphatemia was not directly inhibiting
calcitriol production. Nevertheless, a previous study in normal
subjects and patients with hyperparathyroidism or nephro-
lithiasis showed an inverse correlation between plasma phos-
phate levels and calcitriol levels [25]. In the present study the
negative correlation between the calcitriol/GFR ratio and Tmp
favors a relationship between renal phosphate handling and
calcitriol production, perhaps under the influence of PTH.
Lastly, different causes of renal failure may have variable
effects on calcitriol production. It would appear that in the
presence of MCRF, factors other than GFR alone are influ-
encing calcitriol levels.
The precise cause of the rise in calcitriol during calcium
deprivation in this study is not completely clear. The fall in
serum calcium in both groups, the fall in Tmp in the normal
subjects, and the rise in NcAMP and PTH in the MCRF patients
would be consistent with a role for PTH. Certainly, a previous
study of a low calcium diet in normal subjects demonstrated a
rise in PTH [26]. The cause of the fall in serum calcium was
presumably due to reduced entry of gut calcium into the
circulation, insufficiently compensated for by a homeostatic rise
in PTH and calcitriol. The cause of the fall in serum calcitriol
concentrations in the normal subjects from day two is unclear.
Whatever the stimulus, in absolute terms the peak calcitriol
levels obtained in MCRF patients were much lower than in
normal subjects.
Table 4. Results (mean sD) of 25 hydroxyvitamin D and
magnesium at the beginning and end of the calcium deprivation test
Normal subjects MCRF subjects
Day 0 Day 7 Day 0 Day 7
25 hydroxy
vitamin D
nmollliter 86 43 80 23 91 34 78 44
Magnesium
mmol/iiter 0.86 0.02 0.82 0.02 0.88 0.10 0.79 0.05
Despite the reduced functional renal mass in MCRF the
calcium deprivation study indicated that some reserve synthetic
capacity for calcitriol remained. When considered in absolute
terms this synthetic reserve was much smaller than in normal
subjects. However, in relation to the functional renal mass, as
calculated by the calcitriol/GFR ratio, there was no difference
in maximal calcitriol production between normal subjects and
MCRF patients. The cause of the low calcitriol production in
the MCRF subjects in the basal state, despite reserve synthetic
capacity, is uncertain especially in view of the strong evidence
for hyperparathyroidism in these subjects, one of the best
recognized stimulators of calcitriol production [9]. It is possible
that the slight elevation of plasma phosphate or an alteration in
renal phosphate handling shown by the low Tm in the MCRF
patients resulted in inhibition of calcitriol production, particu-
larly as there is in vivo and in vitro evidence for the important
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stimulatory effect of low phosphate diets on calcitriol produc-
tion [25—29]. A recent study in children, showing that phosphate
restriction in children with moderate chronic renal failure
resulted in a rise in calcitriol levels, accords with this role for
phosphate retention [6]. In the present study, plasma phosphate
levels were higher in the chronic renal failure patients than in
controls, suggesting a more significant degree of renal failure
than in other studies [5]. The similar values for 24-hour urine
creatinine, phosphate and urea in the normal and MCRF groups
excludes a difference in lean body mass, dietary phosphate
intake or dietary protein intake to account for the difference in
calcitriol levels. The lower 24-hour urine calcium in the MCRF
subjects may reflect reduced gut calcium absorption [10], or the
effect of PTH to increase renal calcium conservation.
It is clear from this and other studies that impaired calcitriol
production is a major feature of mild to moderate chronic renal
failure. The presence of significant hyperparathyroidism has
also been demonstrated but the normal calcium levels in the
MCRF subjects in the present study is evidence against the
hypothesis that the hyperparathyroidism is secondary to phos-
phate induced hypocalcemia, as suggested by Bricker [30], and
supports in vitro evidence demonstrating little effect of slight
elevations in plasma phosphate on reducing circulating ionized
calcium levels [311. Rather, this study supports previous sug-
gestions [5, 6, 32] that in MCRF, reduced calcitriol production
associated with abnormal renal phosphate handling is the prime
abnormality. This results secondarily in hyperparathyroidism
because of reduced gut calcium absorption [10] and bone
resorption [II], both of which would result in hypocalcemia
corrected by hyperparathyroidism. The demonstration of calci-
triol receptors in parathyroid tissue [33], the inhibition of
messenger ribonucleic acid for preproparathyroid hormone by
calcitriol [34], together with evidence in man of the suppressive
effect of calcitriol on PTH levels in acute [35]and chronic renal
failure [361, all raise the possibility that in MCRF the low
calcitriol levels permit the development of hyperparathyroidism
directly by loss of the inhibitory effect of calcitriol on the
parathyroid gland.
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